Skip to main content

Phase 1/2b study of Ibrutinib with Carlfizomib with R/R Myeloma

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Pharmacyclics, Inc.

Start Date

January 20, 2013

End Date

September 15, 2021
 

Administered By

Duke Cancer Institute

Awarded By

Pharmacyclics, Inc.

Start Date

January 20, 2013

End Date

September 15, 2021